MegaGen and BIOLASE Invest Nearly $1 Million to Expand Manufacturing Infrastructure at Corona, California Facility

Rhea-AI Summary

BIOLASE (BIOLQ), a MegaGen company, announced a nearly $1 million construction and equipment investment at its Corona, California manufacturing facility. The project expands production capacity, adds cleanroom space, upgrades fiber and laser rooms, and enhances warehouse and employee areas to support Waterlase and Epic dental laser technologies.

Outside the U.S., MegaGen will lead BIOLASE laser sales, while from July 1, 2026 MegaGen America will support U.S. commercial operations, training and customer service.

Positive

• Nearly $1 million manufacturing infrastructure investment at Corona facility
• New cleanroom construction and upgraded laser and fiber rooms
• Enhanced warehouse, product flow and expanded employee support spaces
• Supports long-term supply stability for Waterlase and Epic laser systems
• MegaGen to lead international sales and clinical onboarding for BIOLASE lasers
• MegaGen America to support U.S. commercial operations from July 1, 2026

Negative

• None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Investment supports expanded production capacity, cleanroom construction, fiber and laser room upgrades, and long-term supply stability for Waterlase and Epic dental laser technologies.

Investment	Purpose	Facility Focus	Market Model	Core Message
Nearly $1 million dollar Corona construction project investment summary	Increase manufacturing capacity, quality systems support and supply stability	Laser room, fiber room, cleanroom, warehouse, product/material flow and employee spaces	MegaGen-led global sales expansion; MegaGen America-led U.S. support	Long-term commitment to innovation, quality continuity and clinical laser adoption

FOOTHILL RANCH, Calif. and CORONA, Calif., June 25, 2026 /PRNewswire/ -- BIOLASE, a MegaGen company and global leader in dental laser technology, today announced a significant investment in its Corona, California manufacturing operations, underscoring the company's long-term commitment to production capacity, quality, supply stability and continued innovation in dental laser care.

The Corona construction project represents a nearly $1 million dollar investment in manufacturing infrastructure, including demolition and new construction for production-support spaces, cleanroom construction, laser room and fiber room improvements, product and material warehouse enhancements, wall finishing upgrades, and expanded employee spaces including cafeteria, changing room and lunchroom areas.

This significant investment in advanced equipment and manufacturing capabilities is intended not only to increase production capacity to meet growing demand, but also to support scalable operations and uphold BIOLASE's commitment to quality, reliability, and manufacturing excellence for years to come.

In addition to enhancing manufacturing capacity and operational efficiency, the investment supports a broader strategic vision following BIOLASE's integration into the MegaGen family. The initiative further strengthens the Corona facility's role as a hub for scientific innovation and advanced manufacturing, while expanding global access to BIOLASE laser technologies through MegaGen's international distribution network and clinical education infrastructure.

Outside the United States, MegaGen is expected to take the lead in sales operations for BIOLASE laser technologies, with additional human and material resources allocated to strengthen market development, distributor support, clinical onboarding, and training. In the United States, beginning July 1, 2026, BIOLASE's commercial operations, including sales, customer support, and training activities, will be supported by MegaGen America and its expanded U.S. commercial organization, enhancing local capabilities and responsiveness while maintaining the high standards of product quality and customer experience that customers know and trust.

"Southern California has been an important technology center for BIOLASE for decades, and we are investing here because the next era of dental laser innovation requires both world-class science and disciplined manufacturing execution," said Jung Hwan Lim, COO, Sr. Vice President, BIOLASE. "This project strengthens our ability to support clinicians with the quality, reliability and continuity they expect from Waterlase and Epic laser technologies."

BIOLASE's Waterlase all-tissue laser systems and Epic diode laser systems are used by clinicians to support a broad range of dental procedures and patient care models. With the Corona facility improvements, the company is investing in the manufacturing backbone required to support dentists, specialists, distributors and training partners as laser adoption continues to expand.

The Corona facility investment also reflects MegaGen's broader commitment to combining clinical insight, rapid innovation and disciplined manufacturing execution across its global dental technology portfolio. By aligning BIOLASE's laser engineering and manufacturing capabilities with MegaGen's commercial, education and service network, the companies aim to help more clinicians seamlessly integrate advanced laser technology into everyday dental care.

"This is about more than construction," said Brian Park, Director of Strategic Planning, BIOLASE. "It is about creating the infrastructure, educational pathways and market support needed to make proven dental laser technology more accessible and easier for dentists to adopt with confidence."

The construction program is part of BIOLASE and MegaGen's ongoing effort to raise the bar on quality, reliability and service continuity for clinicians in the United States and around the world.

BIOLASE^®, Waterlase^® and Waterlase iPlus^®, and Epic^® are registered trademarks of BIOLASE MG LLC.
For updates and information on BIOLASE and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Instagram at www.instagram.com/biolase_official, and LinkedIn at www.linkedin.com/company/biolase/.

About BIOLASE
BIOLASE, a MegaGen company, is a medical device company and global leader in dental laser technology. The company develops, manufactures and markets proprietary dental laser systems, including the Waterlase and Epic families of laser technologies, designed to help dental professionals deliver precise, minimally invasive and patient-friendly care.

About MegaGen Implant
MegaGen Implant is a global dental technology company known for clinician-driven implant systems, digital dentistry solutions, clinical education and service innovation. Together with BIOLASE, MegaGen is working to unite advanced implant, laser and digital technologies to support clinicians and improve patient care worldwide.

Media Contact
Denise Arterberry
Marketing Manager, BIOLASE
darterberry@biolase.com
949.226.8190

View original content to download multimedia:https://www.prnewswire.com/news-releases/megagen-and-biolase-invest-nearly-1-million-to-expand-manufacturing-infrastructure-at-corona-california-facility-302810187.html

SOURCE BIOLASE

FAQ

What manufacturing investment did BIOLASE (BIOLQ) announce for its Corona, California facility in June 2026?

BIOLASE announced a nearly $1 million construction and equipment investment at its Corona manufacturing facility. According to BIOLASE, funds will expand production capacity, add cleanroom space, upgrade laser and fiber rooms, and improve warehouse and employee areas to support dental laser technologies.

How will MegaGen and MegaGen America support BIOLASE (BIOLQ) sales and operations after July 1, 2026?

Outside the U.S., MegaGen will lead BIOLASE laser sales operations globally. According to BIOLASE, from July 1, 2026 MegaGen America will support U.S. sales, customer service and training through an expanded commercial organization, aiming to improve local responsiveness and clinical onboarding.

Which BIOLASE (BIOLQ) dental laser technologies are supported by the Corona facility upgrades?

The Corona upgrades support Waterlase all-tissue and Epic diode dental laser systems. According to BIOLASE, the investment strengthens manufacturing for a broad range of dental procedures, helping dentists, specialists, distributors and training partners as clinical laser adoption continues to expand worldwide.

How does the nearly $1 million Corona facility project affect BIOLASE (BIOLQ) production capacity and supply stability?

The project is intended to increase production capacity and support long-term supply stability. According to BIOLASE, new cleanroom construction, laser and fiber room improvements, and warehouse enhancements aim to uphold quality, reliability and continuity for Waterlase and Epic laser customers globally.

What is the strategic purpose of BIOLASE and MegaGen's Corona construction program for BIOLQ investors?

The program aligns BIOLASE manufacturing with MegaGen’s global commercial and education network. According to BIOLASE, it aims to combine clinical insight, rapid innovation and disciplined manufacturing, making proven dental laser technology more accessible and easier for dentists to adopt with confidence.

When did BIOLASE (BIOLQ) announce the Corona manufacturing expansion and what markets does it target?

BIOLASE announced the Corona expansion on June 25, 2026, targeting U.S. and global markets. According to BIOLASE, the upgraded facility will support MegaGen-led international sales and MegaGen America-led U.S. commercial efforts for its Waterlase and Epic dental laser technologies.